Tercica launches Increlex patient database

By Elaine Rigoli

Tampa, Fla., June 21 - Tercica, Inc. said it has launched the first registry for patients treated with Increlex (mecasermin [rDNA origin] injection) therapy and will introduce the Increlex Growth Forum Database (IGFD) Registry to pediatric endocrinologists this week.

Tercica said the objective of the registry is to gather long-term, real-world information on how patients are responding to Increlex therapy.

With increasing numbers of patients on Increlex therapy available for analysis, pediatric endocrinologists will be able to gain a better understanding of the condition itself, the company explained in a news release.

Based in Brisbane, Calif., Tercica is a biopharmaceutical company focused on the development and commercialization of products to improve endocrine health.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.